1.01.05
2022:06:26 23:10:13.572
moyamoya
419487
38
1
3
3
NCT05160454
16NC24
Great Ormond Street Hospital for Children NHS Foundation Trust
OTHER
NIRS to Evaluate Haemodynamic Reserve in Paediatric Moyamoya
NIRS to Evaluate Haemodynamic Reserve in Paediatric Moyamoya
NIRS moyamoya
November 2021
Suspended
COVID19
No
February 14, 2018
Actual
June 30, 2022
Anticipated
June 30, 2022
Anticipated
November 8, 2019
December 2, 2021
December 16, 2021
Actual
December 2, 2021
December 16, 2021
Actual
Sponsor
Great Ormond Street Hospital for Children NHS Foundation Trust
OTHER
No
No
No
Near infrared spectroscpy is a validated method of evaluating cerebral blood flow. The aim in this pilot study to explore its use in children with moyamoya disease.
Moyamoya disease is a cerebrovascular condition in which there is chronic brain hypoperfusion. As surgery can possibly augment brain blood flow, a method for evalutaing cerebrovascualr reserve would be helpful in selecting patients for intervention.
Near infrared spectroscopy (NIRS) is a validated non-invasive method of evaluating cerebral blood flow. We aim to investigate the feasibility and tolerability of using NIRS haemodynamic reserve in children with moyamoya and controls by evaluating cerebral blood flow in the baseline state and after breath-holding.
Feasibility will be assessed by how many successful studies are carried out. Tolerability will be assessed by asking children some simple questions about their experience.
Moyamoya
Interventional
Not Applicable
Non-Randomized
Single Group Assignment
patients and controls
Other
None (Open Label)
20
Anticipated
patient
Active Comparator
child with moyamoya
Device: near infrared spectroscopy
control
Active Comparator
unaffected control
Device: near infrared spectroscopy
Device
near infrared spectroscopy
evaluate cerebral blood flow with and without breatholding
control
patient
Number of NIRS studies that can be completed in moyamoya patients
how many studies can be completed
2years
Patient questionnaire to evaluate children's experience of NIRS in moyamoya
ask children re their experience
2years
Inclusion Criteria: Patients with moyamoya and unaffected healthy controls -
Exclusion Criteria: age <6
-
Accepts Healthy Volunteers
All
6 Years
18 Years
Child
Adult
Great Ormond Street Hospital for Children NHS Foundation Trust
London
WC1N 3JH
United Kingdom
No
June 27, 2022
D000009072
Moyamoya Disease
D000002340
Carotid Artery Diseases
D000002561
Cerebrovascular Disorders
D000001927
Brain Diseases
D000002493
Central Nervous System Diseases
D000009422
Nervous System Diseases
D000002539
Cerebral Arterial Diseases
D000020765
Intracranial Arterial Diseases
D000001157
Arterial Occlusive Diseases
D000014652
Vascular Diseases
D000002318
Cardiovascular Diseases
M11184
Moyamoya Disease
Moyamoya
high
M4746
Carotid Artery Diseases
low
M4962
Cerebrovascular Disorders
low
M4356
Brain Diseases
low
M4894
Central Nervous System Diseases
low
M4940
Cerebral Arterial Diseases
low
M21674
Intracranial Arterial Diseases
low
M3617
Arterial Occlusive Diseases
low
M16552
Vascular Diseases
low
T3892
Moyamoya Disease
Moyamoya
high
BC10
Nervous System Diseases
BC14
Heart and Blood Diseases
All
All Conditions
Rare
Rare Diseases
NCT05050344
RECHMPL21_0343
University Hospital, Montpellier
OTHER
Moya Moya Syndrome With or Withtout Sickle Cell Disease
Descriptive Bicentric Study of Moya Moya Syndrome and Disease in Sickle Cell Disease Patients and Not Sickle Cell Disease
BMM-ScD
June 2021
Recruiting
No
May 1, 2021
Actual
December 1, 2022
Anticipated
December 1, 2022
Anticipated
June 10, 2021
September 17, 2021
September 20, 2021
Actual
September 18, 2021
September 24, 2021
Actual
Sponsor
University Hospital, Montpellier
OTHER
No
No
No
Moya Moya disease or syndrome ar characterized by a progressive or occlusion of the intracranial carotid arteries and their mainproximal branches, followed by the development of fragile neovessels at the base of the skull, leding to a high risk of both ischemic and hemorragic stroke over time. Moya Moya syndrome are associated to a variety of disease, which main frequent is sickle cell disease (SCD).
Among patients with SCD who had suffered from at least one ischemic stroke, the prevalence of moya moya syndrome was estimated up to 43%. In general, therapeutic strategies in Moya Moya to prevent first ever ou recurrent stroke can be divided into conservative medical treatment and surgical revascularisation (direct bypass, indirect bypass or combined bypass).
The aim of this study is to compare prognosis of patients with Moya Moya syndrome associated with sickle cell disease or not. The investigators retrospectiveluy analysed medical chart from 2010 to 2021 of patients with Moya Moya disease or syndrome at two French university hospitals (including a center of the french West Indies where prevalence of sickle cell disease is high). The diagnosis was based on angiography or MRI records showing uni- or bilateral stenosis of distal intracranial internal carotide arteries or middle cerebral arteries associated wirh classic collateral network.
Main endpoint will be comparison of a composite outcome defined as time from Moya Moya diagnosis to first or recurrent stroke or bad prognosis achivement (defined by modified Rankin score >2)
Moya Moya Disease
Moya Moya syndrome
Moya Moya
Observational
No
Cohort
Retrospective
50
Anticipated
time from Moya Moya diagnosis to first or recurrent stroke or bad prognosis achivement
composite endpoint of outcome defined as time from Moya Moya diagnosis to first or recurrent stroke or bad prognosis achivement (defined by modified Rankin score >2)
1 day
Time from MM diagnosis to Stroke
Time from MM diagnosis to Stroke
1 day
poor prognosis or death
poor prognosis or death (mRS> 2) at the last clinical evaluation.
1 day
Inclusion criteria:
age >=15
patients at diagnosis of Moya Moya disease and syndrome
Exclusion criteria:
misclassified patients
clinical diagnosis of MM not confirmed by angiography or MRI
No
All
15 Years
Child
Adult
Older Adult
patients >=15 years of age at diagnosis of Moya Moya disease and syndrome from january 2010 to february 2021 at Montpellier and Martinique University Hospital
Non-Probability Sample
Nicolas Gaillard, MD
Contact
4 67 33 74 13
33
n-gaillard@chu-montpellier.fr
Estelle BRITHMER, Resident
University Hospital, Montpellier
Principal Investigator
Uhmontpellier
Recruiting
Montpellier
34295
France
Nicolas Gaillard, MD
Contact
4 67 33 74 13
33
n-gaillard@chu-montpellier.fr
Estelle Brithmer
Contact
e-Brithmer@chu-montpellier.fr
Undecided
NC
June 27, 2022
D000009072
Moyamoya Disease
D000000755
Anemia, Sickle Cell
D000000745
Anemia, Hemolytic, Congenital
D000000743
Anemia, Hemolytic
D000000740
Anemia
D000006402
Hematologic Diseases
D000006453
Hemoglobinopathies
D000030342
Genetic Diseases, Inborn
D000002340
Carotid Artery Diseases
D000002561
Cerebrovascular Disorders
D000001927
Brain Diseases
D000002493
Central Nervous System Diseases
D000009422
Nervous System Diseases
D000002539
Cerebral Arterial Diseases
D000020765
Intracranial Arterial Diseases
D000001157
Arterial Occlusive Diseases
D000014652
Vascular Diseases
D000002318
Cardiovascular Diseases
M3237
Anemia, Sickle Cell
Sickle Cell Disease
high
M15507
Syndrome
low
M11184
Moyamoya Disease
Moya Moya
high
M3222
Anemia
low
M8699
Hemolysis
low
M3225
Anemia, Hemolytic
low
M3227
Anemia, Hemolytic, Congenital
low
M8642
Hematologic Diseases
low
M8691
Hemoglobinopathies
low
M22839
Genetic Diseases, Inborn
low
M4746
Carotid Artery Diseases
low
M4962
Cerebrovascular Disorders
low
M4356
Brain Diseases
low
M4894
Central Nervous System Diseases
low
M4940
Cerebral Arterial Diseases
low
M21674
Intracranial Arterial Diseases
low
M3617
Arterial Occlusive Diseases
low
M16552
Vascular Diseases
low
T5229
Sickle Cell Anemia
Sickle Cell Disease
high
T3892
Moyamoya Disease
Moya Moya
high
BC15
Blood and Lymph Conditions
BC16
Diseases and Abnormalities at or Before Birth
All
All Conditions
BC23
Symptoms and General Pathology
BC10
Nervous System Diseases
BC14
Heart and Blood Diseases
Rare
Rare Diseases
NCT03613701
8157113
Affiliated Hospital to Academy of Military Medical Sciences
OTHER
Relationship Between Endothelial Progenitor Cells and Revascularization Effect of Moyamoya Disease
Relationship Between Endothelial Progenitor Cells and Revascularization Effect of Moyamoya Disease
REPCREMMD
January 2019
Unknown status
Recruiting
No
September 1, 2017
Actual
September 1, 2019
Anticipated
December 1, 2020
Anticipated
July 29, 2018
August 2, 2018
August 3, 2018
Actual
January 29, 2019
January 31, 2019
Actual
Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
OTHER
No
No
Moyamoya disease is a chronic cerebrovascular diseaseļ¼The typical pathological manifestations are the stenosis or occlusion of the distal internal carotid artery and/or middle cerebral artery, and the proximal anterior cerebral artery. Meanwhile, the abnormal vascular net, which is the smokey vessel, occurs at the bottom of the brain. Currently the pathogenesis of this disease is unknown. Limited studies have reported the expression of endothelial progenitor cells (EPCs) in moyamoya disease, but the results were inconsistent. Some investigators believe that the number of EPCs in peripheral blood of patients with moyamoya disease is increased, while others believe that the number of EPCs in peripheral blood of moyamoya patients is reduced. Therefore, the investigators need to find a more accurate detection method to confirm the growth of EPC in patients with moyamoya disease. At the same time, whether there is endothelial injury in patients with smoke disease, and the expression of endothelial cells (CEC) in patients with smoke disease, there is no research on this aspect at home and abroad.
Objective: Detect the expression of endothelial progenitor cells and endothelial cells from peripheral blood of patients with moyamoya disease, and to assess the relationship between clinical characteristics.
Design: A single center study, and planned to enroll 120 patients. The present study was to detect the quantities of EPC from peripheral blood in Moyamoya disease by flow cytometry, and to identify the relationship of endothelial progeIlitor cells and effect of the revascularization on Moyamoya disease. The present study also use cerebral ischemia animal model foe intervention experiment, to explore whether EPC can promote vascular remodeling effect of ischemic cerebrovascular disease, and to provide new thought for the treatment of chronic cerebrovascular disorder.
Moyamoya Disease
Moyamoya disease
Endothelial progenitor cells
revascularization
Observational
Yes
6 Months
Case-Control
Prospective
120
Anticipated
Moyamoya disease patients
Moyamoya disease patients/Healthy volunteers
Expression of endothelial progenitor cells and endothelial cells in peripheral blood
Expression of endothelial progenitor cells and endothelial cells in peripheral
2017.9-2018.8
Inclusion Criteria:
Whole-brain vessels angiography or magnetic resonance arteriography (MRA) has the following manifestations: stenosis or occlusion of terminal internal carotid artery or the anterior cerebral artery and/or initiating middle cerebral artery; In the arterial phase, the abnormal smokey vascular net near the occlusive or stenosis lesion can be seen.
For patients with stable stroke, there was no acute or subacute cerebral infarction or cerebral hemorrhage, and at least 3 months before the last cerebral infarction or cerebral hemorrhage events.
Exclusion Criteria:
Exclude atherosclerosis, autoimmune diseases, meningitis, intracranial tumors, multiple neurofibromatosis, Down syndrome, craniocerebral trauma, radiation injury, and other underlying diseases that may cause smoke.
Acute or subacute cerebral infarction or cerebral hemorrhage were excluded.
Accepts Healthy Volunteers
All
18 Years
60 Years
Adult
Health volunteers' inclusion criteria:
Age between 18-60;
Male or female;
Exclusion criteria:
Exclude the volunteers with history of cerebrovascular disease and heart disease.
Probability Sample
Lian Duan, Chief
Contact
0086-10-66947156
keyan307@163.com
Lian Duan, Chief
The 307th Hospital of Military Chinese People's Liberation Army
Study Chair
The 307th Hospital of Military Chinese People's Liberation Army
Recruiting
Beijing
Beijing
100071
China
Lian Duan, Chief
Contact
0086-10-66947156
keyan307@163.com
No
June 27, 2022
D000009072
Moyamoya Disease
D000002340
Carotid Artery Diseases
D000002561
Cerebrovascular Disorders
D000001927
Brain Diseases
D000002493
Central Nervous System Diseases
D000009422
Nervous System Diseases
D000002539
Cerebral Arterial Diseases
D000020765
Intracranial Arterial Diseases
D000001157
Arterial Occlusive Diseases
D000014652
Vascular Diseases
D000002318
Cardiovascular Diseases
M11184
Moyamoya Disease
Moyamoya Disease
high
M4746
Carotid Artery Diseases
low
M4962
Cerebrovascular Disorders
low
M4356
Brain Diseases
low
M4894
Central Nervous System Diseases
low
M4940
Cerebral Arterial Diseases
low
M21674
Intracranial Arterial Diseases
low
M3617
Arterial Occlusive Diseases
low
M16552
Vascular Diseases
low
T3892
Moyamoya Disease
Moyamoya Disease
high
BC10
Nervous System Diseases
BC14
Heart and Blood Diseases
All
All Conditions
Rare
Rare Diseases